Dear Dr. Renukaprasad A R,  Nearly half of all deaths worldwide are caused by cardiovascular diseases, with ischemic heart disease and acute coronary syndrome accounting for most deaths.
Dual antiplatelet therapy (DAPT) is a crucial part of the recovery process for those with the acute coronary syndrome and has proven successful in secondary prevention in ACS patients.
Ticagrelor, an efficient antiplatelet drug, demonstrates higher efficacy in lowering the rate of cardiovascular adverse events.
Check out this article summarizing different clinical trials investigating the efficacy of ticagrelor and highlighting their outcomes in terms of safety, efficacy, and mortality profile. | 
No comments:
Post a Comment